^
    Back
    Association details:
    Biomarker:PD-L1 underexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Akalux (cetuximab sarotalocan) (EGFR-targeted-dye conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    SITC 2020
    Title:

    622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

    Published date:
    11/09/2020
    Excerpt:
    PD-L1 expression prior to RM-1929 treatment was assessed by immunohistochemistry in 18 out of 30 patients enrolled...These results suggest that rHNSCC patients with lower PD-L1 expression levels may be more responsive to RM-1929 treatment…
    DOI:
    http://dx.doi.org/10.1136/jitc-2020-SITC2020.0622
    Trial ID:
    NCT02422979